Destiny Pharma on track for commercial agreement for NTCD-M3 drug
(Alliance News) - Destiny Pharma PLC on Thursday said partnering negotiations for its NTCD-M3 clinical programme are nearing finalisation.
Read moreTue, 06th Jul 2021 10:35
(Alliance News) - Destiny Pharma PLC on Thursday said partnering negotiations for its NTCD-M3 clinical programme are nearing finalisation.
Read more(Alliance News) - Destiny Pharma PLC on Wednesday said it has finalised development plans for phase three testing of its late-stage clinical asset, XF-73 Nasal, which aims to prevent post-surgical staphylococcal infections.
Read more(Sharecast News) - Biotechnology company Destiny Pharma has finalised plans for phase-three studies of its late-stage clinical asset 'XF-73 Nasal', it announced on Wednesday.
Read more(Alliance News) - Destiny Pharma PLC on Tuesday said it had started a safety study to enable its XF-73 treatment to be labelled as an Investigational New Drug.
Read more(Sharecast News) - Biotechnology developer Destiny Pharma announced the start of an investigational new drug (IND)-enabling safety study with its novel 'XF-73 Dermal' formulation.
Read more(Alliance News) - Destiny Pharma PLC on Thursday reported a widened interim loss, as it progresses two key clinical assets.
Read more(Alliance News) - Destiny Pharma PLC on Wednesday announced that it had received positive feedback from the European Medicine Agency on its NTCD-M3 phase 3 development plans.
Read more(Sharecast News) - Clinical stage biotechnology company Destiny Pharma has received "positive feedback" from the European Medicine Agency regarding the proposed Phase III development programme of its new antibiotic treatment.
Read moreFriday 2 September | |
Ashmore Group PLC | Full Year Results |
Monday 5 September | |
Belvoir Group PLC | Half Year Results |
Dechra Pharmaceuticals PLC | Full Year Results |
Tuesday 6 September | |
Accrol Group Holdings PLC | Full Year Results |
Alumasc Group PLC | Full Year Results |
Ashtead Group PLC | Q1 Results |
Capricorn Energy PLC | Half Year Results |
Gamma Communications PLC | Half Year Results |
Headlam Group PLC | Half Year Results |
Inspired PLC | Half Year Results |
IQE PLC | Half Year Results |
Lords Group Trading PLC | Half Year Results |
Luceco PLC | Half Year Results |
Michelmersh Brick Holdings PLC | Half Year Results |
Midwich Group PLC | Half Year Results |
NCC Group PLC | Full Year Results |
PCI-PAL PLC | Full Year Results |
Pebble Group PLC | Half Year Results |
Quixant PLC | Half Year Results |
STV Group PLC | Half Year Results |
WAG Payment Solutions PLC | Half Year Results |
WANdisco PLC | Half Year Results |
Wednesday 7 September | |
Bakkavor Group PLC | Half Year Results |
Barratt Developments PLC | Full Year Results |
Equals Group PLC | Half Year Results |
M Winkworth PLC | Half Year Results |
Malin Corp PLC | Half Year Results |
Petropavlovsk PLC | Half Year Results |
Somero Enterprises Inc | Half Year Results |
Tissue Regenix Group PLC | Half Year Results |
WH Smith PLC | Trading Statement |
Thursday 8 September | |
Arecor Therapeutics PLC | Half Year Results |
Cairn Homes PLC | Half Year Results |
Curtis Banks Group PLC | Half Year Results |
Darktrace PLC | Full Year Results |
Destiny Pharma PLC | Half Year Results |
Duke Royalty Ltd | Full Year Results |
Emis Group PLC | Half Year Results |
Energean PLC | Half Year Results |
Funding Circle Holdings PLC | Half Year Results |
Genus PLC | Full Year Results |
International Public Partnerships Ltd | Half Year Results |
Melrose Industries PLC | Half Year Results |
Mpac Group PLC | Half Year Results |
Oakley Capital Investments Ltd | Half Year Results |
Open Orphan PLC | Half Year Results |
Restaurant Group PLC | Half Year Results |
Safestore Holdings PLC | Q3 Results |
Severfield PLC | Full Year Results |
Shield Therapeutics PLC | Half Year Results |
SourceBio International PLC | Half Year Results |
Spire Healthcare Group PLC | Half Year Results |
Sylvania Platinum Ltd | Full Year Results |
Vistry Group PLC | Half Year Results |
Copyright 2022 Alliance News Limited. All Rights Reserved. |
(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Tuesday and not separately reported by Alliance News:
Read more(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Tuesday and not separately reported by Alliance News:
Read more(Sharecast News) - Clinical-stage biotechnology company Destiny Pharma has received an award from the Cystic Fibrosis Foundation, it announced on Tuesday.
Read moreDestiny Pharma PLC - Brighton-based clinical-stage biotechnology company - Receives undisclosed grant from Maryland-based non profit Cystic Fibrosis Foundation for a study on its drug candidate XF-73 on disease-causing bacteria MRSA.
Read moreDestiny Pharma PLC - Brighton-based clinical-stage biotechnology company - New data on its XF-73 drug show that it can boost the effectiveness of current standard of care antibiotics when used in combinational therapy. The new in-vitro data stemmed from experiments by studies at the School of Dentistry, Cardiff University, for the potential for XF-based drugs to enhance the effectiveness of key antibacterial treatments. When combined with polymyxin B, a last resort antibacterial drug used to treat life-threatening lung bacterial infections, XF-73 enhanced polymyxin B potency against Pseudomonas aeruginosa, a top priority WHO bacterial pathogen, by 4-fold, the research found.
Read moreDestiny Pharma PLC - Brighton-based clinical-stage biotechnology company - Starts new research programme in the US on oral mucositis, an inflammation of the mouth that is a common side effect of chemotherapy and radiotherapy. Firm tests its experimental drug candidate XF-73 as potential preventive medicine to ease suffering from oral mucositis. Explains that XF-73 has shown unique antimicrobial properties in phase 2 clinical trials.
Read more